Fig. 1

Efficacy and safety of bendamustine lymphodepletion before lisocabtagene maraleucel. A. Best response after liso-cel. Light blue represents complete response, blue represents partial response, and dark blue represents no response. B. Progression-free survival after liso-cel. C. Overall survival after liso-cel. D. CRS and ICANS of any grade incidence. E. Infusion setting of liso-cel infusion. Light gray represents the inpatient setting and dark gray represents outpatient setting. F. Hematologic toxicities within 30 days after liso-cel infusion. Dot plots highlight individual nadir values of neutrophils, hemoglobin and platelets levels. Shadows of yellow background highlight the range of specific abnormal levels. G. Blood counts over time during the 4 weeks after liso-cel infusion. Values are expressed as median and 95% confidence interval error bars. Shadows of yellow background highlight the range of specific abnormal levels. H. Blood counts at 3 months after liso-cel infusion. Dot plots highlight individual nadir values of lymphocytes, neutrophils, hemoglobin, and platelets levels. Shadows of yellow background highlight the range of specific abnormal levels

Abbreviations: CR: complete response; CRS: cytokine release syndrome; ICANS: immune effector cell-associated neurotoxicity syndrome; N: number; NR: not response; PR: partial response